302 related articles for article (PubMed ID: 26420338)
1. Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer.
Lin CC; Huang WL; Wei F; Su WC; Wong DT
Expert Rev Mol Diagn; 2015; 15(11):1427-40. PubMed ID: 26420338
[TBL] [Abstract][Full Text] [Related]
2. A liquid biopsy in primary lung cancer.
Yoneda K; Imanishi N; Ichiki Y; Tanaka F
Surg Today; 2019 Jan; 49(1):1-14. PubMed ID: 29644440
[TBL] [Abstract][Full Text] [Related]
3. Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer.
Sun W; Yuan X; Tian Y; Wu H; Xu H; Hu G; Wu K
J Hematol Oncol; 2015 Jul; 8():95. PubMed ID: 26227959
[TBL] [Abstract][Full Text] [Related]
4. Liquid biopsy genotyping in lung cancer: ready for clinical utility?
Huang WL; Chen YL; Yang SC; Ho CL; Wei F; Wong DT; Su WC; Lin CC
Oncotarget; 2017 Mar; 8(11):18590-18608. PubMed ID: 28099915
[TBL] [Abstract][Full Text] [Related]
5. The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer.
Huang WL; Wei F; Wong DT; Lin CC; Su WC
Biomed Res Int; 2015; 2015():340732. PubMed ID: 26448936
[TBL] [Abstract][Full Text] [Related]
6. The Emerging Role of "Liquid Biopsies," Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations.
Esposito A; Criscitiello C; Trapani D; Curigliano G
Curr Oncol Rep; 2017 Jan; 19(1):1. PubMed ID: 28110461
[TBL] [Abstract][Full Text] [Related]
7. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor cells and DNA for real-time EGFR detection and monitoring of non-small-cell lung cancer.
He J; Tan W; Ma J
Future Oncol; 2017 Apr; 13(9):787-797. PubMed ID: 28073294
[TBL] [Abstract][Full Text] [Related]
9. What do we need to make circulating tumour DNA (ctDNA) a routine diagnostic test in lung cancer?
Bernabé R; Hickson N; Wallace A; Blackhall FH
Eur J Cancer; 2017 Aug; 81():66-73. PubMed ID: 28609695
[TBL] [Abstract][Full Text] [Related]
10. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
[TBL] [Abstract][Full Text] [Related]
11. Role of circulating-tumor DNA analysis in non-small cell lung cancer.
Jiang T; Ren S; Zhou C
Lung Cancer; 2015 Nov; 90(2):128-34. PubMed ID: 26415994
[TBL] [Abstract][Full Text] [Related]
12. Tumor-educated platelet as liquid biopsy in lung cancer patients.
Liu L; Lin F; Ma X; Chen Z; Yu J
Crit Rev Oncol Hematol; 2020 Feb; 146():102863. PubMed ID: 31935617
[TBL] [Abstract][Full Text] [Related]
13. Liquid Biopsy in Solid Malignancy.
Scarlotta M; Simsek C; Kim AK
Genet Test Mol Biomarkers; 2019 Apr; 23(4):284-296. PubMed ID: 30916594
[TBL] [Abstract][Full Text] [Related]
14. Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.
Yang M; Topaloglu U; Petty WJ; Pagni M; Foley KL; Grant SC; Robinson M; Bitting RL; Thomas A; Alistar AT; Desnoyers RJ; Goodman M; Albright C; Porosnicu M; Vatca M; Qasem SA; DeYoung B; Kytola V; Nykter M; Chen K; Levine EA; Staren ED; D'Agostino RB; Petro RM; Blackstock W; Powell BL; Abraham E; Pasche B; Zhang W
J Hematol Oncol; 2017 May; 10(1):100. PubMed ID: 28472989
[TBL] [Abstract][Full Text] [Related]
15. [Research Advancement on EGFR Mutation Detection of Cell-free DNA and Tumor Cell in Peripheral Blood of Patients with Non-small Cell Lung Cancer].
Zhang Y; Xu Y; Wang M
Zhongguo Fei Ai Za Zhi; 2016 Nov; 19(11):766-772. PubMed ID: 27866520
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor T790M testing in progressed lung cancer: A review of sensitive methods for analysis of tissue and liquid biopsy samples.
Chougule A; Basak S
Indian J Cancer; 2017 Dec; 54(Supplement):S45-S54. PubMed ID: 29292708
[TBL] [Abstract][Full Text] [Related]
17. [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].
Pécuchet N; Legras A; Laurent-Puig P; Blons H
Ann Pathol; 2016 Jan; 36(1):80-93. PubMed ID: 26803564
[TBL] [Abstract][Full Text] [Related]
18. Liquid Biopsy in Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society.
Sholl LM; Aisner DL; Allen TC; Beasley MB; Cagle PT; Capelozzi VL; Dacic S; Hariri LP; Kerr KM; Lantuejoul S; Mino-Kenudson M; Raparia K; Rekhtman N; Roy-Chowdhuri S; Thunnissen E; Tsao M; Vivero M; Yatabe Y
Arch Pathol Lab Med; 2016 Aug; 140(8):825-9. PubMed ID: 27195432
[TBL] [Abstract][Full Text] [Related]
19. EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs.
Liang Z; Cheng Y; Chen Y; Hu Y; Liu WP; Lu Y; Wang J; Wang Y; Wu G; Ying JM; Zhang HL; Zhang XC; Wu YL
Cancer Lett; 2017 Sep; 403():186-194. PubMed ID: 28642172
[TBL] [Abstract][Full Text] [Related]
20. Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management.
Vendrell JA; Mau-Them FT; Béganton B; Godreuil S; Coopman P; Solassol J
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28146051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
